Program
Foralumab Nasal
Its studies are mostly in Amyotrophic Lateral Sclerosis · Multiple System Atrophy, led by Tiziana Life Sciences.
Furthest: phase 2, since Mar 6, 20253 company-led studies, 2 open or runningNext primary completion: Apr 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tiziana Life Sciences | 32 open or running | phase 2since Mar 6, 2025 | Mar 6, 2025 | Apr 1, 2027phase 2 · NCT06868628 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2025First study: phase 2 study in Multiple System AtrophyFirst studyNCT06868628 · 5 planned · United States
- Mar 11, 2025Phase 1 study in SafetyNCT06879067 · 27 enrolled · United States
- Jun 30, 2026Phase 2 study in Amyotrophic Lateral SclerosisNCT07688239 · 44 planned · United States
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Multiple System AtrophyNCT06868628
- Jul 2027Primary completion: phase 2 study in Amyotrophic Lateral SclerosisNCT07688239
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07688239Amyotrophic Lateral Sclerosis · United States | 2 | By invitation | Jul 2027 | 44 |
| NCT06879067Safety · United States | 1 | Completed | Jul 23, 2019 | 27 |
| NCT06868628Multiple System Atrophy · United States | 2 | Recruiting | Apr 1, 2027 | 5 |
How it is read
Names in the registry
- “Foralumab Nasal”, 3 entries
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 1 study
- Multiple System Atrophy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.